AC
MRTX

Armistice Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Armistice Capital’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-500,000
Closed -$29.4M – 432
2023
Q4 		$29.4M Sell
500,000
-864,098
-63% -$48.6M 0.4% 45
2023
Q3 		$59.4M Sell
1,364,098
-2,613,902
-66% -$93.3M 0.91% 19
2023
Q2 		$144M Buy
3,978,000
+286,000
+8% +$11.8M 2.08% 5
2023
Q1 		$137M Buy
3,692,000
+204,000
+6% +$9.18M 1.98% 7
2022
Q4 		$158M Buy
3,488,000
+1,588,000
+84% +$103M 2.76% 3
2022
Q3 		$133M Sell
1,900,000
-148,000
-7% -$11M 2.3% 9
2022
Q2 		$137K Buy
2,048,000
+684,000
+50% +$43.5M 2.4% 4
2022
Q1 		$112M Buy
1,364,000
+528,000
+63% +$54M 2.17% 7
2021
Q4 		$123M Buy
836,000
+126,000
+18% +$19.6M 2.01% 6
2021
Q3 		$126M Buy
710,000
+50,000
+8% +$8.04M 2.13% 5
2021
Q2 		$107M Buy
660,000
+124,000
+23% +$19.9M 1.91% 7
2021
Q1 		$91.8M Buy
536,000
+264,000
+97% +$52.3M 2.11% 5
2020
Q4 		$59.7M Buy
272,000
+104,000
+62% +$22.5M 2.03% 10
2020
Q3 		$27.9M Sell
168,000
-104,000
-38% -$14.2M 1.01% 40
2020
Q2 		$31.1M Sell
272,000
-40,000
-13% -$3.88M 1.36% 26
2020
Q1 		$24M Buy
312,000
+192,000
+160% +$17.2M 1.48% 24
2019
Q4 		$15.5M Buy
+120,000
New +$11.6M 0.89% 34

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Armistice Capital's MRTX Position: Q1 2024 in Review

Armistice Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 500,000 shares — an estimated $29.4M sold.

Armistice Capital first reported a position in MRTX in Q4 2019 and held it in 17 quarters. The position peaked at $158M in Q4 2022. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Armistice Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Armistice Capital sold 500,000 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $29.4M.
  • Armistice Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2019 and held it in 17 quarters.
  • Armistice Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $158M in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Armistice Capital's 13F filing for Q1 2024, filed 15 May 2024.